Nevro Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nevro stock.
View analyst ratings for Nevro or view top-rated stocks.

Wall Street analysts have given Nevro a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nevro wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Nevro is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Nevro.

Nevro Corp. (NYSE:NVRO) issued its quarterly earnings data on Tuesday, February, 23rd. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.12. Nevro had a negative trailing twelve-month return on equity of 30.25% and a negative net margin of 24.46%.
View Nevro's earnings history.

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 37.6% and is now trading at $151.12.
View which stocks have been most impacted by COVID-19.

Nevro updated its FY 2021 After-Hours earnings guidance on Wednesday, February, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $430-450 million, compared to the consensus revenue estimate of $451.19 million.

14 equities research analysts have issued 1-year target prices for Nevro's stock. Their forecasts range from $100.00 to $217.00. On average, they expect Nevro's stock price to reach $181.38 in the next year. This suggests a possible upside of 20.0% from the stock's current price.
View analysts' price targets for Nevro or view top-rated stocks among Wall Street analysts.

9 employees have rated Nevro CEO D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among Nevro's employees.

Some companies that are related to Nevro include Teleflex (TFX), Insulet (PODD), Abiomed (ABMD), NovoCure (NVCR), Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), Haemonetics (HAE), Inspire Medical Systems (INSP), Integra LifeSciences (IART), Tandem Diabetes Care (TNDM), Inari Medical (NARI), ICU Medical (ICUI), iRhythm Technologies (IRTC) and Glaukos (GKOS).
View all of NVRO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.70%), BlackRock Inc. (10.81%), Jackson Square Partners LLC (3.58%), Lord Abbett & CO. LLC (2.18%), Nuveen Asset Management LLC (1.35%) and Northern Trust Corp (1.30%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Castleark Management LLC, Jennison Associates LLC, Victory Capital Management Inc., Lisanti Capital Growth LLC, State of Wisconsin Investment Board, and ClariVest Asset Management LLC. Company insiders that have sold Nevro company stock in the last year include Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro or view top insider-selling stocks.

NVRO stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, BlackRock Inc., Jackson Square Partners LLC, Thornburg Investment Management Inc., Tiger Eye Capital LLC, Nuveen Asset Management LLC, Healthcare of Ontario Pension Plan Trust Fund, and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle.
View insider buying and selling activity for Nevro or or view top insider-buying stocks.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVRO stock can currently be purchased for approximately $151.12.

Nevro has a market capitalization of $5.23 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis.

Nevro employs 853 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro is headquartered at 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]